would improve endothelial dysfunction, prevent or induce the regression of the atherosclerotic lesions and reduce the risk of diabetes complications. Disclosure The authors report no conﬂicts of interest in this work. References Al-Rasheed NM, Willars GB, Brunskill NJ. 2006. C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol, 17:986–95. Brand K, Page S, Rogler G, et al. 1996. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest, 97:1715–22. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414:813–20. Castellani P, Viale G, Dorcaratto A, et al. 1994. The ﬁbronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer, 59:612–8. Chakrabarti S, Khan ZA, Cukiernik M, et al. 2004. C-peptide and retinal microangiopathy in diabetes. Exp Diabesity Res, 5:91–6. [DCCT] The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the develop- ment and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329:977–86. Denk A, Wirth T, Baumann B. 2000. NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev, 11:303–20. De La Tour DD, Raccah D, Jannot MF, et al. 1998. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia, 41:1080–4. DiPetrillo K, Gesek FA. 2004. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol, 24:352–9. Fioretto P, Steffes MW, Sutherland DE, et al. 1998. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 339:69–75. Fiorina P, Folli F, Zerbini G, et al. 2003. Islet transplantation is associ- ated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol, 14:2150–8. Forst T, Kunt T, Pohlmann T, et al. 1998a. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest, 101:2036–41. Forst T, Kunt T, Pfutzner A, et al. 1998b. New aspects on biological activity of C-peptide in IDDM patients. Exp Clin Endocrinol Diabetes, 106:270–6. Grunberger G, Qiang X, Li Z, et al. 2001. Molecular basis for the insulino- mimetic effects of C-peptide. Diabetologia, 44:1247–57. Hansen A, Johansson BL, Wahren J, et al. 2002. C-peptide exerts beneﬁcial effects on myocardial blood ﬂow and function in patients with type 1 diabetes. Diabetes, 51:3077–82. Hasegawa G, Nakano K, Sawada M, et al. 1991. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int, 40:1007–12. Heliövaara MK, Teppo AM, Karonen SL, et al. 2005. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 7:729–36. Hotamisligil GS. 1999a. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes, 107:119–25. Hotamisligil GS. 1999b. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med, 245:621–5. Vascular Health and Risk Management 2008:4(6) C-peptide and diabetes complications Hotamisligil GS, Murray DL, Choy LN, et al. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A, 91:4854–8. Huang DY, Richter K, Breidenbach A. 2002. Human C-peptide acutely lowers glomerular hyperﬁltration and proteinuria in diabetic rats: a dose-response study. Naunyn Schmiedebergs Arch Pharmacol, 365:67–73. Ido Y, Vindigni A, Chang K, et al. 1997. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science, 277:563–6. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, et al. 1989. Features of endothelial dysfunction in early diabetic nephropathy. Lancet, 1:461–3. Johansson BL, Linde B, Wahren J. 1992. Effects of C-peptide on blood ﬂow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia, 35:1151–8. Johansson BL, Borg K, Fernqvist-Forbes E. 2000. Beneﬁcial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med, 17:181–9. Johansson BL, Wahren J, Pernow J. 2003. C-peptide increases forearm blood ﬂow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab, 285:E864–70. Kalantarinia K, Awad AS, Siragy HM. 2003. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int, 64:1208–13. Karelina TV, Eisen AZ. 1998. Interstitial collagenase and the ED-B oncofetal domain of ﬁbronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prev, 22:438–44. Khan ZA, Cukiernik M, Gonder JR, et al. 2004. Oncofetal ﬁbronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci, 45:287–95. Kitamura T, Kimura K, Jung BD, et al. 2001. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 ﬁbroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J, 355:123–9. Kitazawa M, Shibata Y, Hashimoto S, et al. 2006. Proinsulin C-peptide stimulates a PKC/IkappaB/NF-kappaB signaling pathway to activate COX-2 gene transcription in Swiss 3T3 fibroblasts. J Biochem, 139:1083–8. Kobayashi Y, Naruse K, Hamada Y, et al. 2005. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia, 48:2396–401. Kunt T, Schneider S, Pfutzner A, et al. 1999. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia, 42:465–71. Langer S, Born F, Breidenbach A, et al. 2002. Effect of C-peptide on wound healing and microcirculation in diabetic mice. Eur J Med Res, 7:502–8. Lee TC, Barshes NR, Agee EE. 2006. The effect of whole organ pancreas transplantation and PIT on diabetic complications. Curr Diab Rep, 6:323–7. Li ZG, Zhang W, Sima AA. 2003. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev, 19:375–85. Li ZG, Sima AA. 2004. C-peptide and central nervous system complications in diabetes. Exp Diabesity Res, 5:79–90. Maezawa Y, Yokote K, Sonezaki K, et al. 2006. Inﬂuence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev, 22:313–22. Manzella D, Ragno E, Abbatecola AM, et al. 2003. Residual C-peptide secretion and endothelial function in patients with Type II diabetes. Clin Sci (Lond ), 105:113–18. Marx N, Walcher D, Raichle C, et al. 2004. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol, 24:540–5. 1287